Clinical Use of Lanreotide AG as Initial Therapy in Patients with Advanced, Non-Resectable Well (G1) and Moderate (G2) Differentiated Pancreatic Neuroendocrine Neoplasms (p-NEN)

#2300

Introduction: Lanreotide AG currently is used as standard initial therapy in NETG1 & G2 pancreatic NEN with Ki-67<10%.

Aim(s): The evaluation of clinical use Lanreotide AG as initial systemic therapy in patients with advanced, non-resectable pNEN, based on progression free survival (PFS) in G1 and G2.

Materials and methods: Data sets 374 patients, 56 of them treated initially with Lanreotide AG 120mg, 1x 4 weeks. Responses and AEs were evaluated after each of 4 weeks during clinical follow-up. The primary objective - PFS, based on objective response rate (ORR) evaluated using CT/MRI after 6-month intervals. The clinical efficacy was based on PFS and time to subsequent death/PD. Kaplan –Meier method used to calculate PFS, ORR was classified according to RECIST 1.0

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Cwikla J

Authors: Ćwikła J, Kolasińska-Ćwikła A, Lewczuk-Myślińska A, Pałucki J, Roszkowska-Purska K,

Keywords: advance, non-resectable pancreatic neuroendocrine neoplams, Lanreotide AG systemic therapy,